{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T04:25:32Z","timestamp":1742012732498,"version":"3.38.0"},"reference-count":8,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015820","name":"Taoyuan General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015820","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jmii.2024.11.002","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T08:35:09Z","timestamp":1731573309000},"page":"276-279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug monitoring was conducted for rifapentine among people with HIV receiving dolutegravir containing antiretroviral therapy and latent tuberculosis treatment"],"prefix":"10.1016","volume":"58","author":[{"given":"Jeng-Hung","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Chun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Pin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Hsing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Chun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiu-Wen","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Ting","family":"Shieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1886-0370","authenticated-orcid":false,"given":"Chien-Yu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmii.2024.11.002_bib3","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa1507198","article-title":"A trial of early antiretrovirals and isoniazid preventive therapy in Africa","volume":"373","author":"Danel","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2024.11.002_bib4","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jmii.2023.07.013","article-title":"Effectiveness of second-generation integrase strand-transfer inhibitor-based regimens for antiretroviral-experienced people with HIV who had viral rebound","volume":"56","author":"Chen","year":"2023","journal-title":"J Microbiol Immunol Infect"},{"article-title":"Guidelines approved by the guidelines review committee","year":"2018","series-title":"Latent Tuberculosis Infection: Updated and Consolidated Guidelines for Programmatic Management","key":"10.1016\/j.jmii.2024.11.002_bib5"},{"key":"10.1016\/j.jmii.2024.11.002_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the treatment of latent tuberculosis infection: recommendations from the national tuberculosis controllers association and CDC","volume":"69","author":"Sterling","year":"2020","journal-title":"MMWR Recomm Rep (Morb Mortal Wkly Rep)"},{"key":"10.1016\/j.jmii.2024.11.002_bib7","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1016\/S2352-3018(21)00324-6","article-title":"Use of integrase inhibitors in HIV-associated tuberculosis in high-burden settings: implementation challenges and research gaps","volume":"9","author":"Naidoo","year":"2022","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jmii.2024.11.002_bib8","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1016\/S2352-3018(20)30032-1","article-title":"Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1\/2 trial","volume":"7","author":"Dooley","year":"2020","journal-title":"Lancet HIV"},{"issue":"5","key":"10.1016\/j.jmii.2024.11.002_bib9","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/cid\/ciad730","article-title":"Treatment responses to integrase strand-transfer inhibitor-containing antiretroviral regimens in combination with short-course rifapentine-based regimens for latent tuberculosis infection among people with HIV","volume":"78","author":"Lin","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2024.11.002_bib10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13690-023-01098-z","article-title":"Efficacy and safety of different regimens in the treatment of patients with latent tuberculosis infection: a systematic review and network meta-analysis of randomized controlled trials","volume":"81","author":"Assefa","year":"2023","journal-title":"Arch Publ Health"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118224002081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118224002081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T16:48:55Z","timestamp":1741970935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118224002081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":8,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1684118224002081"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2024.11.002","relation":{},"ISSN":["1684-1182"],"issn-type":[{"type":"print","value":"1684-1182"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug monitoring was conducted for rifapentine among people with HIV receiving dolutegravir containing antiretroviral therapy and latent tuberculosis treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2024.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}